Cargando…

Safety Assessment of an Oral Therapeutic Dose of Firocoxib on Healthy Horses

SIMPLE SUMMARY: This study was conducted to evaluate the effects of oral firocoxib on healthy horses. The drug is a non-steroidal anti-inflammatory medication routinely used in veterinary medicine. The study found that administering firocoxib to the horses did not cause any adverse effects on the st...

Descripción completa

Detalles Bibliográficos
Autores principales: Araújo, Renatha A., Sales, Nathali A. A., Basile, Roberta C., Feringer-Junior, Walter H., Apparício, Maricy, Ferraz, Guilherme C., Queiroz-Neto, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10535825/
https://www.ncbi.nlm.nih.gov/pubmed/37756053
http://dx.doi.org/10.3390/vetsci10090531
_version_ 1785112721066295296
author Araújo, Renatha A.
Sales, Nathali A. A.
Basile, Roberta C.
Feringer-Junior, Walter H.
Apparício, Maricy
Ferraz, Guilherme C.
Queiroz-Neto, Antonio
author_facet Araújo, Renatha A.
Sales, Nathali A. A.
Basile, Roberta C.
Feringer-Junior, Walter H.
Apparício, Maricy
Ferraz, Guilherme C.
Queiroz-Neto, Antonio
author_sort Araújo, Renatha A.
collection PubMed
description SIMPLE SUMMARY: This study was conducted to evaluate the effects of oral firocoxib on healthy horses. The drug is a non-steroidal anti-inflammatory medication routinely used in veterinary medicine. The study found that administering firocoxib to the horses did not cause any adverse effects on the stomach mucosa. However, it slightly reduces the blood’s ability to clot, which was unexpected since the drug was supposed to promote clotting. Overall, firocoxib was deemed safe for horses and can be used to manage inflammation in these animals. Clinicians should be conscious of potential anti-coagulopathy secondary to firocoxib administration with long-term use or critical illness. ABSTRACT: Firocoxib is a non-steroidal anti-inflammatory drug specifically formulated for veterinary medicine and selectively acts on inhibiting the cyclooxygenase 2 enzyme (COX-2). This study evaluated the possible adverse effects of administering oral therapeutic firocoxib on gastric mucosa, hematological parameters, coagulation cascade, and hepatic and renal biochemistry in healthy horses. Nine clinically healthy Arabian horses, approximately 9 years old, received 0.1 mg/kg of oral firocoxib for 14 days. The gastroscopic examination was conducted 1 day before starting treatment (D0) and two days after the last blood collection (D23). Venous blood samples were obtained for laboratory tests on day 1, immediately prior to the initiation of treatment (D1), after 7 and 14 days of treatment (D7 and D14), and 7 days after the conclusion of treatment (D21. No changes were found in the gastroscopic and hematological tests. Coagulation and serum biochemistry levels remain between these species’ average values. However, the increased activated partial thromboplastin time (aPTT) and prothrombin time (PT) indicate reduced blood coagulation capacity, which contradicts the expected effect of treatment with selective COX-2 inhibitors, as these drugs theoretically promote coagulation. Administering firocoxib to horses is safe as it does not cause significant adverse reactions. Therefore, it is a suitable option for managing inflammatory conditions in these animals with attention to an unexpected adverse anti-coagulopathy effect, and further study is warranted.
format Online
Article
Text
id pubmed-10535825
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105358252023-09-29 Safety Assessment of an Oral Therapeutic Dose of Firocoxib on Healthy Horses Araújo, Renatha A. Sales, Nathali A. A. Basile, Roberta C. Feringer-Junior, Walter H. Apparício, Maricy Ferraz, Guilherme C. Queiroz-Neto, Antonio Vet Sci Article SIMPLE SUMMARY: This study was conducted to evaluate the effects of oral firocoxib on healthy horses. The drug is a non-steroidal anti-inflammatory medication routinely used in veterinary medicine. The study found that administering firocoxib to the horses did not cause any adverse effects on the stomach mucosa. However, it slightly reduces the blood’s ability to clot, which was unexpected since the drug was supposed to promote clotting. Overall, firocoxib was deemed safe for horses and can be used to manage inflammation in these animals. Clinicians should be conscious of potential anti-coagulopathy secondary to firocoxib administration with long-term use or critical illness. ABSTRACT: Firocoxib is a non-steroidal anti-inflammatory drug specifically formulated for veterinary medicine and selectively acts on inhibiting the cyclooxygenase 2 enzyme (COX-2). This study evaluated the possible adverse effects of administering oral therapeutic firocoxib on gastric mucosa, hematological parameters, coagulation cascade, and hepatic and renal biochemistry in healthy horses. Nine clinically healthy Arabian horses, approximately 9 years old, received 0.1 mg/kg of oral firocoxib for 14 days. The gastroscopic examination was conducted 1 day before starting treatment (D0) and two days after the last blood collection (D23). Venous blood samples were obtained for laboratory tests on day 1, immediately prior to the initiation of treatment (D1), after 7 and 14 days of treatment (D7 and D14), and 7 days after the conclusion of treatment (D21. No changes were found in the gastroscopic and hematological tests. Coagulation and serum biochemistry levels remain between these species’ average values. However, the increased activated partial thromboplastin time (aPTT) and prothrombin time (PT) indicate reduced blood coagulation capacity, which contradicts the expected effect of treatment with selective COX-2 inhibitors, as these drugs theoretically promote coagulation. Administering firocoxib to horses is safe as it does not cause significant adverse reactions. Therefore, it is a suitable option for managing inflammatory conditions in these animals with attention to an unexpected adverse anti-coagulopathy effect, and further study is warranted. MDPI 2023-08-22 /pmc/articles/PMC10535825/ /pubmed/37756053 http://dx.doi.org/10.3390/vetsci10090531 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Araújo, Renatha A.
Sales, Nathali A. A.
Basile, Roberta C.
Feringer-Junior, Walter H.
Apparício, Maricy
Ferraz, Guilherme C.
Queiroz-Neto, Antonio
Safety Assessment of an Oral Therapeutic Dose of Firocoxib on Healthy Horses
title Safety Assessment of an Oral Therapeutic Dose of Firocoxib on Healthy Horses
title_full Safety Assessment of an Oral Therapeutic Dose of Firocoxib on Healthy Horses
title_fullStr Safety Assessment of an Oral Therapeutic Dose of Firocoxib on Healthy Horses
title_full_unstemmed Safety Assessment of an Oral Therapeutic Dose of Firocoxib on Healthy Horses
title_short Safety Assessment of an Oral Therapeutic Dose of Firocoxib on Healthy Horses
title_sort safety assessment of an oral therapeutic dose of firocoxib on healthy horses
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10535825/
https://www.ncbi.nlm.nih.gov/pubmed/37756053
http://dx.doi.org/10.3390/vetsci10090531
work_keys_str_mv AT araujorenathaa safetyassessmentofanoraltherapeuticdoseoffirocoxibonhealthyhorses
AT salesnathaliaa safetyassessmentofanoraltherapeuticdoseoffirocoxibonhealthyhorses
AT basilerobertac safetyassessmentofanoraltherapeuticdoseoffirocoxibonhealthyhorses
AT feringerjuniorwalterh safetyassessmentofanoraltherapeuticdoseoffirocoxibonhealthyhorses
AT appariciomaricy safetyassessmentofanoraltherapeuticdoseoffirocoxibonhealthyhorses
AT ferrazguilhermec safetyassessmentofanoraltherapeuticdoseoffirocoxibonhealthyhorses
AT queiroznetoantonio safetyassessmentofanoraltherapeuticdoseoffirocoxibonhealthyhorses